Ulcerative Colitis Clinical Trial
Official title:
Comparison of the Efficacy and Safety of Infliximab, as Monotherapy or in Combination With Azathioprine, Versus Azathioprine Monotherapy in Moderate to Severe Active Ulcerative Colitis (Part 1) Comparison of Maintenance Versus Intermittent Infliximab Treatment in Maintaining Remission: A Follow-Up of Efficacy and Safety (Part 2)
Part 1 of this study is a 3-arm, randomized, active-controlled, parallel-group, multicenter,
double-blind, double-dummy, 16-week study to compare the efficacy and safety of infliximab
(IFX), as monotherapy or in combination with azathioprine (AZA) versus AZA monotherapy in
adults with moderate to severe active ulcerative colitis (UC). Participants who qualify at
the Baseline Visit will be eligible to be randomized to one of the three active treatment
groups.
Participants in the IFX/AZA combination therapy and IFX monotherapy cohorts will receive IFX
infusions at Weeks 0, 2, and 6 and daily oral AZA/placebo, respectively; participants in the
AZA cohort will receive daily oral AZA and placebo infusions at Weeks 0, 2, and 6. At Week 8,
all participants will be evaluated for response.
Participants responding to IFX treatment at Week 8, either as monotherapy or in combination
with AZA, will receive one more IFX infusion at Week 14; non-responders to IFX therapy will
receive placebo infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14.
Participants responding to AZA monotherapy at Week 8 will continue on AZA therapy and receive
one placebo infusion at Week 14; nonresponders to AZA will be eligible to receive IFX at
Weeks 8, 10, and 14.
Part 2: Participants in remission on IFX monotherapy or IFX/AZA treatment at Week 16 will be
randomized to either maintenance or intermittent open-label IFX treatment; randomization will
be stratified based on oral AZA/placebo treatment in Part 1. Oral AZA/placebo treatment will
continue to be double-blinded. All participants will continue to receive oral AZA/ placebo
for the duration of the study.
Participants randomized to maintenance IFX treatment will receive scheduled IFX infusions
every 8 weeks beginning at Week 22 (Week 6 for direct entry). If participants lose response,
or if treatment has to be discontinued because of an adverse event, these participants are
considered treatment failures, and should be followed up for safety at the scheduled 6-month
visits (Weeks 38, 62, and 94 [Weeks 22, 46, and 78 for direct entry]). These participants
will receive standard of care per their personal physician.
Participants randomized to intermittent IFX treatment will be evaluated every 8 weeks.
Participants will receive IFX only upon relapse of disease. Treatment with IFX will be
initiated at Weeks 0, 2, and 6 of the individual treatment cycle and will continue every 8
weeks until remission is regained. Throughout the study, individual treatment cycles will be
repeated whenever a subject relapses.
In addition, to facilitate enrollment into Part 2, participants who received treatment
outside of Part 1 and who are in remission on IFX with or without AZA/6-mercaptopurine (6-MP)
will be allowed to enter directly into Part 2. In the Czech Republic, direct entry into Part
2 of the study is not allowed.
A higher than expected incidence of serious infusion reactions observed in the intermittent
treatment arm of another study (Protocol P04563, NCT0358670) conducted in participants with
moderate to severe psoriasis resulted in the termination of that study. Based on the
similarities in study design between the intermittent treatment arm of P04563 and the
intermittent treatment arm of Part 2 of this study, enrollment to Part 2 of this study was
put on hold, for precautionary reasons. At the same time, all participants already enrolled
in the intermittent treatment arm of Part 2 were asked to discontinue from the trial. In
October 2009, a decision was made by the sponsor to terminate the whole study (Part 1 and 2).
At that time, participants enrolled in Part 1 of the study were allowed to complete their
treatment up to Week 16.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |